It is possible that the enhanced levels of serum PEDF in CAD or CAD-risk patients reflect a response to hypertriglyceridemia, whereby the body is attempting to correct the perturbance in the lipid metabolism system [27]. The gene discussed is SERPINF1; the disease is coronary artery disorder.